GPC-201 is under clinical development by GPCR Therapeutics and currently in Phase II for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase II drugs for Multiple Myeloma (Kahler Disease) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GPC-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GPC-201 overview
GPC-201 (GP01CR01) is under development for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumor. The drug candidate acts by targeting the GPCR heteromer of C-X-C chemokine receptor type 4 (CXCR-4) and beta-2 adrenergic receptor (ADRB2).
GPCR Therapeutics overview
GPCR Therapeutics (GPCR) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of cancer. The company’s Gai-protein coupled receptor (CXCR4) products pipeline includes GPC201 and GPC20X which are used in the treatment of multiple myeloma, acute myeloid leukemia, and solid tumors. Its CXCR4 receptor binds to CXCL12 for regulating tumor growth, angiogenesis, metastasis, and therapeutic resistance. GPCR also develops a combination therapy with GPC-100 and propranolol for the mobilization of stem cells for multiple myeloma. The company was funded by LB Investment, CKD Venture Capital, Capstone, Mirae Asset Venture Investment, Pharos Asset Investment, TaiGen Biotechnology, Intervest, Shinhan Investment Corp, and Smilegate Investment, among others. It operates with an additional office in California, the US. GPCR is headquartered in Seoul, South Korea.
For a complete picture of GPC-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.